DC-CIK cell immune therapy and its effect on related indicators in patients with lung cancer
WEI Xicui
WANG Huixia
JIA Ruzhen
ZHANG Zhicang
Abstract：Objective To investigate the effect of DC-CIK cellular immune therapy in the treatment of patients with lung cancer and relevant indicators.Methods From January 2014 to January 2016 in department of respiratory,Shaanxi province Shaanxi Baoji People's Hospital,80 lung cancer patients were included as the research object.They were randomly divided into observation group and control group;the control group were treated with cisplatin combined with gemcitabine,the observation group also added with DCCIK;evaluate the curative effect of patients;3 months before and after treatment,patients' functional status was assessed,and the blood samples were collected from peripheral blood T cell subsets and serum levels of IFN-γ,IL-4,TNF-alpha,TGF-beta were analyzed,and calculate the ratio of Th1/Th2;at the end of 18 months follow-up,adverse reactions were evaluated.Results After treatment,the total efficiency of the observation group and disease control rate were significantly higher than those in control group (47.50％ vs.32.50％,x2 =4.688,P =0.030;95.00％ vs.77.50％,x2 =12.912,P =0.000);after treatment,the observation group's KPS scores were significantly higher than those in the control group (t =12.422,P =0.000);the observation group's CD3 +,CD4 +/CD8 + and NK were significantly higher than those in the control group (t =5.107,P =0.000;t =4.24.1,P =0.000,t =8.959,P =0.000);observation group's blood IFN-γ,IL-4,TNF-alpha level,Th1/Th2 were significantly higher than the control group (t =24.736,P =0.000;t =15.556,P =0.000;t =12.293,P =0.000;t =7.757,P =0.000),TGF beta levels significantly lower than the control group (t =10.824,P =0.000);the observation group's nausea and vomiting,the function of liver and kidney damage,thrombocytopenia incidence was significantly lower than the control group (x2 =15.603,P =0.000;x2 =15.603,P =0.000;x2 =5.128,P =0.024);the survival curve of patients in the observation group were better than that of the control group,and the difference was statistically significant (P ＜ 0.05).Conclusion DC-CIK cell immunotherapy can effectively improve the clinical efficacy,reduce the incidence of adverse reactions,and effectively regulate the levels of immune cells and cytokines in patients with lung cancer.
Keywords：DC-CIK cell immunotherapyLung cancerClinical efficacyImmune cellsCytokines
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 476-479,485 )